These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38606592)

  • 1. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells.
    Li S; Li X; Yang YB; Wu SF
    Apoptosis; 2024 Aug; 29(7-8):1198-1210. PubMed ID: 38553612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors.
    Akrida I; Makrygianni M; Nikou S; Mulita F; Bravou V; Papadaki H
    Pathol Res Pract; 2024 Oct; 262():155551. PubMed ID: 39153238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanosignaling YAP/TAZ-TEAD Axis Regulates the Immunomodulatory Properties of Mesenchymal Stem Cells.
    Yoshii H; Kajiya M; Yoshino M; Morimoto S; Horikoshi S; Tari M; Motoike S; Iwata T; Ouhara K; Ando T; Yoshimoto T; Shintani T; Mizuno N
    Stem Cell Rev Rep; 2024 Jan; 20(1):347-361. PubMed ID: 37917410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
    Pobbati AV; Hong W
    Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct YAP/TAZ-TEAD inhibitor paves the way toward realizing cancer mechanomedicine.
    Papavassiliou KA; Gargalionis AN; Papavassiliou AG
    Pharmacol Res; 2024 Aug; 206():107287. PubMed ID: 38944219
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of the Hippo-YAP/TAZ Pathway in Epithelioid Hemangioendothelioma and its Potential as a Therapeutic Target.
    Suto H
    Anticancer Res; 2024 Oct; 44(10):4147-4153. PubMed ID: 39348982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
    Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
    Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
    El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
    Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
    Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
    Niu RJ; Zheng QC; Zhang HX
    J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
    Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
    ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.